Drugs & Aging

, Volume 18, Issue 8, pp 575–585

Drug Treatment of the Complications of Cirrhosis in the Older Adult

Therapy in Practice


Several age-related changes occur in the structure and functions of the liver. The volume of the liver decreases, despite an increase in the size of hepatocytes, suggesting loss of liver cells. There are decreases in hepatic blood flow, the synthesis of urea and cholesterol, and the metabolism of drugs. Moreover, the regenerative capacity of liver becomes less efficient.

Certain caveats are important when treating older patients with liver disease. Strict dietary restrictions, such as a low protein diet, should be avoided in the elderly (unless the patient is encephalopathic) because these patients are often undernourished to start with. Similarly, strict salt restriction should be enforced with caution, since it makes food less palatable and may take away what little desire such patients have to eat. Diuretic doses should be adjusted carefully because of greater risks of azotaemia and electrolyte disturbances in the elderly. Extra vigilance should be exercised in the early detection of infections that are more likely to occur in patients with cirrhosis. For example, spontaneous bacterial peritonitis can be missed in the elderly because of poor systemic (fever, abdominal tenderness) and laboratory responses (leucocytosis). In patients presenting with acute variceal bleeding, it is better to err on the side of underhydration than overhydration because of the risk of congestive heart failure. Vasopressin should be avoided in the elderly, since this drug has a high probability of precipitating an ischaemic event. Older patients do not tolerate β-blockers as well as younger individuals and may require other treatment strategies for the prevention of variceal rebleeding episodes. Hepatic encephalopathy, especially the milder form, needs careful assessment because it can be easily confused with senile dementia syndromes.

Cirrhosis is a premalignant condition and patients are at increased risk of developing hepatocellular carcinoma (HCC), a tumour seen predominantly in the elderly. All patients with cirrhosis should be maintained on a lifelong screening programme consisting of a 6-monthly assessment of α-fetoprotein and an imaging study, since early detection provides the only hope for cure of HCC.

The only definitive treatment of cirrhosis is liver transplantation. Advanced age is not a contraindication to transplantation, and survival in older patients (aged >60 years) is comparable to that in younger individuals.


  1. 1.
    Wynne HA, Cope E, Mutch E, et al. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology 1989; 9: 297–301PubMedCrossRefGoogle Scholar
  2. 2.
    Sato T, Tauchi H. The formation of enlarged and giant mitochondria in the aging process of human hepatic cells. Acta Pathol Jpn 1975; 25: 403–12PubMedGoogle Scholar
  3. 3.
    Watanabe T, Tanaka Y. Age-related alterations in the size of the human hepatocytes: study of mononuclear and binuclear cells. Virchows Archiv 1982; 39: 9–20PubMedCrossRefGoogle Scholar
  4. 4.
    Geokas MC, Haverback BJ. The aging gastrointestinal tract. Am J Surg 1969; 117: 881–92PubMedCrossRefGoogle Scholar
  5. 5.
    Bender AD. The effect of increasing age on the distribution of peripheral blood flow in man. J Am Geriatr Soc 1965; 13: 192–8PubMedGoogle Scholar
  6. 6.
    James OFW. Parenchymal liver disease in the elderly. Gut 1997; 41: 430–2PubMedCrossRefGoogle Scholar
  7. 7.
    Hale WE, Stewart RB, Marks RG. Haematological and biochemical laboratory values in an ambulatory elderly population: an analysis of the effects of age, sex, and drugs. Age Aging 1983; 12: 275–84CrossRefGoogle Scholar
  8. 8.
    Einarsson K, Nilsell K, Leijd B, et al. Influence of age on secretion of cholesterol and synthesis of bile acids by the liver. N Engl J Med 1985; 313: 277–82PubMedCrossRefGoogle Scholar
  9. 9.
    Woodhouse KW, James OFW. Hepatic drug metabolism and aging. Br Med Bull 1990; 46: 22–35PubMedGoogle Scholar
  10. 10.
    Greenblatt DJ, Sellers EM, Shader RI. Drug therapy: drug disposition in old age. N Engl J Med 1982; 306: 1081–8PubMedCrossRefGoogle Scholar
  11. 11.
    Schnegg MI, Lautergerg BH. Quantitative liver function in the liver assessed by galactose elimination capacity, aminopyrine demethylation and caffeine clearance. J Hepatol 1986; 3: 164–71PubMedCrossRefGoogle Scholar
  12. 12.
    Liu Y, Guyton KZ, Gorospe M, et al. Age-related decline in mitogen activated protein kinase activity in epidermal growth factor-stimulated rat hepatocytes. J Biochem 1996; 271: 3604–7Google Scholar
  13. 13.
    Wang E. Senescent human fibroblasts resist programmed cell death, and failure to suppress bc 12 is involved. Cancer Res 1995; 55: 2284–92PubMedGoogle Scholar
  14. 14.
    Poynard T, Bedossa P, Opolon P, et al. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825–32PubMedCrossRefGoogle Scholar
  15. 15.
    Conn HO, Atterbury CE. Cirrhosis. In: Schiff L, Schiff ER, editors. Diseases of the liver. 6th ed. Philadelphia (PA): Lippincott, 1987: 725–864Google Scholar
  16. 16.
    Wood LJ, Massie D, McLean AJ, et al. Renal sodium retention in cirrhosis: tubular site and relation to hepatic dysfunction. Hepatology 1988; 8: 831–6PubMedCrossRefGoogle Scholar
  17. 17.
    Runyon BA. Management of adult patients with ascites caused by cirrhosis. Hepatology 1998; 27: 264–72PubMedCrossRefGoogle Scholar
  18. 18.
    Arroyo V, Gines P, Gerbes A, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome. Hepatology 1996; 23: 164–76PubMedCrossRefGoogle Scholar
  19. 19.
    Rossle M, Ochs A, Gulberg V, et al. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342: 1701–7PubMedCrossRefGoogle Scholar
  20. 20.
    Lake JR. The role of transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med 2000; 342: 1745–7PubMedCrossRefGoogle Scholar
  21. 21.
    Runyon BA, McHutchison JG, Antillon MR, et al. Short-course versus long course antibiotic treatment of spontaneous bacterial peritonitis. Gastroenterology 1991; 100: 1737–42PubMedGoogle Scholar
  22. 22.
    Sort P, Navasa M, Arroyo V, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 341: 403–9PubMedCrossRefGoogle Scholar
  23. 23.
    Follo A, Llovet JM, Navasa M, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994; 20: 1495–501PubMedCrossRefGoogle Scholar
  24. 24.
    Runyon BA, Van Epps DE. Diuresis of cirrhotic ascites increases its opsonic activity and may help prevent spontaneous bacterial peritonitis. Hepatology 1986; 6: 396–9PubMedCrossRefGoogle Scholar
  25. 25.
    Tito L, Rimola A, Gines P, et al. Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988; 8: 27–31PubMedCrossRefGoogle Scholar
  26. 26.
    Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 12: 716–24PubMedCrossRefGoogle Scholar
  27. 27.
    Bernard B, Grange JD, Nguyen Khac E, et al. Antibiotic prophylaxis for prevention of bacterial infections in cirrhotic patients with ascites: a meta-analysis. Digestion 1998; 59Suppl. 2: 54–7PubMedCrossRefGoogle Scholar
  28. 28.
    Pauwels A, Mostefa-Kara N, Debenes B, et al. Systemic antibiotic prophylaxis after gastrointestinal hemorrhage in cirrhotic patients with high risk of infection. Hepatology 1996; 24: 802–6PubMedGoogle Scholar
  29. 29.
    Bernard B, Grange JD, Nguyen Khac E, et al. Antibiotic pro phylaxis for the prevention of bacterial infections in patients with cirrhosis after upper gastrointestinal bleeding: a meta-analysis. Hepatology 1999; 29: 1655–61PubMedCrossRefGoogle Scholar
  30. 30.
    Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. J Hepatology 2000; 32: 142–53CrossRefGoogle Scholar
  31. 31.
    Inadomi J, Sonnenberg A. Cost-analysis of prophylactic antibiotics in spontaneous bacterial peritonitis. Gastroenterology 1997; 113: 1289–94PubMedCrossRefGoogle Scholar
  32. 32.
    Terg R, Llano K, Cobas SM, et al. Effects of oral ciprofloxacin on aerobic gram-negative fecal flora in patients with cirrhosis: results of short- and long-term administration with daily and weekly dosages. J Hepatol 1998; 29: 437–42PubMedCrossRefGoogle Scholar
  33. 33.
    Campillo B, Duperyon C, Richardet J-P, et al. Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin. Clin Infect Dis 1998; 26: 1066–70PubMedCrossRefGoogle Scholar
  34. 34.
    D’Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. Hepatology 1995; 22: 332–54PubMedGoogle Scholar
  35. 35.
    Pagliaro L, D’Amico G, Sorensen TIA, et al. Prevention of first bleeding in cirrhosis: a meta-analysis of randomized trials of nonsurgical treatment. Ann Intern Med 1992; 117: 59–70PubMedGoogle Scholar
  36. 36.
    Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981; 80: 800–9PubMedGoogle Scholar
  37. 37.
    Westaby D, Hayes P, Gimson AE, et al. Controlled trial of injection sclerotherapy for active variceal bleeding. Hepatology 1989; 9: 274–7PubMedCrossRefGoogle Scholar
  38. 38.
    Sarin SK, Lamba GS, Kumar M, et al. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med 1999; 340: 988–93PubMedCrossRefGoogle Scholar
  39. 39.
    Bernard B, Lebrec D, Mathurin P, et al. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology 1997; 25: 63–70PubMedCrossRefGoogle Scholar
  40. 40.
    Villanueva C, Balanzo J, Novella MT, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for prevention of variceal rebleeding. N Engl J Med 1996; 334: 1624–9PubMedCrossRefGoogle Scholar
  41. 41.
    Angeli P, Volpin R, Gerunda G, et al. Reversal of Type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29: 1691–7CrossRefGoogle Scholar
  42. 42.
    Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999; 30: 870–5PubMedCrossRefGoogle Scholar
  43. 43.
    Guevara M, Gines P, Bandi JC, et al. Transjugular portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology 1998; 28: 416–22PubMedCrossRefGoogle Scholar
  44. 44.
    Gines A, Escorsell A, Gines P, et al. Incidence, predictive factors and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229–36PubMedGoogle Scholar
  45. 45.
    Conn HO. Animal versus vegetable protein diet in hepatic encephalopathy. J Intern Med 1993; 233: 369–71PubMedCrossRefGoogle Scholar
  46. 46.
    Camma C, Fiorello F, Tine F, et al. Lactilol in treatment of chronic hepatic encephalopathy: a meta-analysis. Dig Dis Sci 1993; 38: 916–22PubMedCrossRefGoogle Scholar
  47. 47.
    Conn HO, Leevy CM, Vlachevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portalsystemic encephalopathy: a double blind controlled trial. Gastroenterology 1977; 72: 573–83PubMedGoogle Scholar
  48. 48.
    El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999: 340: 745–50PubMedCrossRefGoogle Scholar
  49. 49.
    MacMahon M, James OFW. Liver disease in the elderly. J Clin Gastroenterol 1994; 18: 330–4CrossRefGoogle Scholar
  50. 50.
    Hanazaki K, Kajikawa S, Shimozawa N, et al. Hepatic resection for hepatocellular carcinoma in the elderly. J Am Coll Surg 2001; 192: 38–46PubMedCrossRefGoogle Scholar
  51. 51.
    Kew MC. Tumors of the liver. In: Zakin D, Boyer TD, editors. Hepatology: a textbook of liver disease. 3rd ed. Philadelphia (PA): WB Saunders, 1996: 1513–48Google Scholar
  52. 52.
    Yersiz H, Shaked A, Olthoff K, et al. Correlation between donor age and the pattern of liver graft recovery after transplantation. Transplantation 1995; 60: 790–4PubMedGoogle Scholar
  53. 53.
    Oh CK, Sanfey HA, Pelletier SJ, et al. Implications of advanced donor age on the outcome of liver transplantation. Clin Transplant 2000; 14: 286–90CrossRefGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  1. 1.Baylor College of MedicineHoustonUSA
  2. 2.Digestive Diseases Section (111D)VAMedical CenterHoustonUSA

Personalised recommendations